Stock Analysis

3 Growth Companies With High Insider Ownership To Watch

OM:SLP B
Source: Shutterstock

As global markets respond to easing inflation and strong earnings reports, particularly in the U.S., investors are witnessing a rebound in major stock indices. Amidst this backdrop, growth companies with high insider ownership can present intriguing opportunities, as insider stakes often signal confidence in a company's future prospects.

Top 10 Growth Companies With High Insider Ownership

NameInsider OwnershipEarnings Growth
Clinuvel Pharmaceuticals (ASX:CUV)10.4%26.2%
SKS Technologies Group (ASX:SKS)29.7%24.8%
Propel Holdings (TSX:PRL)36.8%38.9%
CD Projekt (WSE:CDR)29.7%30.6%
Pharma Mar (BME:PHM)11.9%56.2%
Medley (TSE:4480)34%27.2%
On Holding (NYSE:ONON)19.1%29.7%
Brightstar Resources (ASX:BTR)16.2%84.3%
Elliptic Laboratories (OB:ELABS)26.8%121.1%
Findi (ASX:FND)35.8%110.9%

Click here to see the full list of 1467 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc., a biotech research company, develops therapeutic drugs for immuno-oncology and neurodegenerative diseases with a market cap of ₩1.54 trillion.

Operations: The company's revenue segment is derived entirely from its biotechnology startups, amounting to ₩32.32 billion.

Insider Ownership: 30.4%

Earnings Growth Forecast: 50.3% p.a.

ABL Bio is poised for substantial growth, with earnings forecasted to rise 50.32% annually and revenue expected to outpace the market at 25.5% per year. Despite a highly volatile share price recently, the company aims for profitability within three years, surpassing average market growth rates. However, its projected Return on Equity remains low at 9.1%. Recent conference presentations highlight ongoing innovation efforts in protein engineering without significant insider trading activity noted recently.

KOSDAQ:A298380 Ownership Breakdown as at Jan 2025
KOSDAQ:A298380 Ownership Breakdown as at Jan 2025

Swedish Logistic Property (OM:SLP B)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Swedish Logistic Property AB is a real estate company focused on acquiring, developing, and managing logistics properties in Sweden with a market cap of SEK10.26 billion.

Operations: The company's revenue primarily comes from its investment properties, amounting to SEK671 million.

Insider Ownership: 11.3%

Earnings Growth Forecast: 21.2% p.a.

Swedish Logistic Property is experiencing significant expansion, acquiring multiple logistics properties with a total value exceeding SEK 2 billion. These acquisitions are strategically located and include long-term leases with major tenants like PostNord and Mitsubishi. Despite forecasted earnings growth of 21.2% annually, the company's interest coverage remains a concern. Trading at a favorable price-to-earnings ratio of 24.2x compared to industry peers, SLP's revenue growth outpaces the Swedish market but remains under 20%.

OM:SLP B Earnings and Revenue Growth as at Jan 2025
OM:SLP B Earnings and Revenue Growth as at Jan 2025

RemeGen (SEHK:9995)

Simply Wall St Growth Rating: ★★★★★☆

Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of HK$12.65 billion.

Operations: The company's revenue from biopharmaceutical research, service, production, and sales amounts to CN¥1.52 billion.

Insider Ownership: 11.4%

Earnings Growth Forecast: 51.2% p.a.

RemeGen Co., Ltd. is experiencing robust revenue growth, with a 58% year-on-year increase projected for 2024, reaching RMB 1.72 billion. Despite this, the company remains unprofitable but has reduced its net loss by approximately 3%. Recent board changes include appointing Mr. Huang Guobin as an independent non-executive director, potentially influencing strategic decisions. RemeGen's innovative HER2-targeting ADC therapy shows significant promise in treating advanced breast cancer, supporting its growth trajectory amidst forecasted annual revenue growth of over 23%.

SEHK:9995 Ownership Breakdown as at Jan 2025
SEHK:9995 Ownership Breakdown as at Jan 2025

Seize The Opportunity

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com